Components of multivalent pneumococcal polysaccharide conjugate vaccine and application thereof

CN119053338APending Publication Date: 2024-11-29SHANGHAI RUIZHOU BIOTECH CO LTD +1
View PDF 0 Cites 2 Cited by

Patent Information

Application Number
CN202380035380.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-04-19
Filing Date
2023-04-19
Publication Date
2024-11-29

AI Technical Summary

Technical Problem

Existing pneumococcal polysaccharide vaccines have poor immunogenicity and low serotype coverage, and polysaccharide-protein conjugate vaccines may cause immunosuppression and cannot effectively prevent pneumococcal infections of multiple pathogenic serotypes.

Method used

Development of a multivalent immunogenic composition containing Streptococcus pneumoniae capsular polysaccharides and carrier proteins from different serotypes, combined with aluminum-based adjuvants, to prepare polysaccharide-protein conjugates through chemical coupling to enhance immunogenicity and reduce the risk of immunosuppression.

Benefits of technology

The composition can effectively prevent invasive infections of 24 different serotypes of pneumococcal bacteria, improve the immune protection rate, reduce the risk of immunosuppression, and provide protection against tetanus toxin infection.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000033_0000
    Figure 00000033_0000
  • Figure 00000033_0001
    Figure 00000033_0001
  • Figure 00000034_0000
    Figure 00000034_0000
Patent Text Reader

Abstract

The present invention relates to multivalent pneumococcal polysaccharide protein conjugates and immunogenicity thereof, and specifically provides an immunogenic composition containing capsular polysaccharides from Streptococcus pneumoniae of different serotypes including at least 2, 8, 9N, 10A, 11A, 12F, 15B, 17F, 20, 22F, and 33F, and a carrier. The immunogenic composition provided by the invention can improve the immunogenicity of polysaccharides of different serotypes, and can prevent invasive infection caused by multiple pneumococci of different serotypes.
Need to check novelty before this filing date? Find Prior Art

Description

Composition and application of multivalent pneumococcal polysaccharide conjugate vaccine Technical Field

[0001] The present invention relates to the field of biomedicine, and in particular to preventing infection by bacterial pathogens through immune multivalent vaccines. Background Art

[0002] Streptococcus pneumoniae (S. pneumoniae) is a Gram-positive diplococcus with a capsule. Nearly 100 serotypes are distinguished based on the composition of its capsular polysaccharide, which is a key pathogenic factor. Normally, S. pneumoniae parasitizes the nasopharynx of healthy individuals. However, when the host environment changes, such as decreased immunity, respiratory viral infections such as measles and influenza, or malnutrition or frailty in the elderly, it can penetrate the mucosal defense system and cause invasive infections. These infections can include entering the lower respiratory tract, causing pneumonia; crossing the blood-brain barrier, causing bacterial meningitis; traversing alveolar epithelial cells and invading vascular endothelial cells to enter the bloodstream, causing bacteremia; and migrating from the nasopharynx into the sinuses, causing sinusitis; and entering the middle ear through the Eustachian tube, causing otitis media, and then continuing to spread non-invasively to other parts of the respiratory tract.

[0003] Pneumococcal disease is a serious global public health problem. According to the World Health Organization, in 2005, approximately 1.6 million people died annually from pneumococcal disease worldwide, including 700,000 to 1 million children under the age of five, most of whom live in developing countries. This demonstrates that pneumococcal disease continues to pose a serious threat to children's health. In developed countries, pneumococcal disease primarily affects children under the age of two, the elderly, and immunocompromised individuals of all ages.

[0004] Pneumococcal disease can be divided into two categories, invasive pneumococcal disease (IPD) and non-invasive pneumococcal disease (NIPD), depending on the site of infection. Antibiotic therapy is the most common treatment, but worldwide, the development of pneumococcal resistance to commonly used antimicrobial drugs has become a growing problem. Years of clinical practice have proven that pneumococcal vaccination is the most cost-effective way to prevent pneumococcal disease.

[0005] Currently available pneumonia vaccines include pneumococcal polysaccharide vaccine (PPSV) and pneumococcal polysaccharide-protein conjugate vaccine (PCV). The 23-valent pneumococcal polysaccharide vaccine (PPSV23) is not suitable for infants and immunocompromised individuals due to its low immunogenicity, lack of immune memory, and lack of boosting activity. Available pneumococcal polysaccharide conjugate vaccines for infants and young children include PCV7, PCV10, and PCV13, but they offer limited serotype coverage, low immune protection rates, and potential immunosuppression. For example, a meta-analysis of literature on the distribution of Streptococcus pneumoniae serotypes in mainland my country showed that between 2000 and 2016, PCV10 serotype coverage was 52.3%, while PCV13 serotype coverage was 68.4%. Furthermore, an increase in the incidence of non-vaccine serotype diseases has been observed following vaccine administration. Furthermore, because the carrier proteins used in polysaccharide-protein conjugate vaccines are also widely used in infant immunization, immunosuppression due to high doses or repeated use of carrier proteins is a potential risk in the clinical use of polysaccharide-protein conjugate vaccines.

[0006] Therefore, the serotype coverage of existing polysaccharide-protein conjugate vaccines is still not ideal. It is of great clinical value to develop multivalent pneumococcal conjugate vaccines to cover a wider range of pathogenic serotypes of pneumococcus, increase non-vaccine serotypes, improve the coverage protection rate and immunogenicity of new multivalent vaccines, and reduce the risk of immunosuppressive effects of carrier proteins.

[0007] Summary of the Invention

[0008] In order to solve the problems of poor immunogenicity of pneumococcal polysaccharide vaccines, low serum coverage of polysaccharide conjugate vaccines, low immunogenicity, and immunosuppression, the present invention provides a multivalent immunogenic composition with wider applicability, stronger immunogenicity and reduced immunosuppression.

[0009] In a first aspect, the present invention provides an immunogenic composition comprising capsular polysaccharides from different serotypes of Streptococcus pneumoniae and a carrier, wherein the serotypes include at least 2, 8, 9N, 10A, 11A, 12F, 15B, 17F, 20, 22F and 33F.

[0010] In one or more embodiments, the serotypes include 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 serotypes selected from the group consisting of 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F, and the serotypes include at least 2, 8, 9N, 10A, 11A, 12F, 15B, 17F, 20, 22F, and 33F. Preferably, the serotypes include the following 20 serotypes: 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, 33F, or the following 24 serotypes: 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F and 33F.

[0011] In one or more embodiments, the carrier is selected from one or more of saline, Ringer's solution, and phosphate buffered saline.

[0012] In one or more embodiments, the immunogenic composition further comprises an adjuvant.

[0013] In one or more embodiments, the adjuvant is an aluminum-based adjuvant.

[0014] In one or more embodiments, the adjuvant comprises one or more selected from aluminum phosphate, aluminum sulfate, aluminum hydroxide, monophosphoryl lipid A, QS21, CpG, MF59, stearoyl tyrosine, Freund's adjuvant and other mucosal adjuvants.

[0015] In one or more embodiments, the weight ratio of capsular polysaccharide from serotype 3, 6B or 12F to any other capsular polysaccharide in the composition is 10:1 to 1:10, such as 5:1 to 1:5, preferably 2:1.

[0016] In one or more embodiments, the composition is a formulation, wherein the concentration of capsular polysaccharides from serotypes 3, 6B, and 12F is independently 1 to 8 μg / dose (preferably 4 μg / dose), and the concentration of the remaining capsular polysaccharides is independently 0.5 to 5 μg / dose (preferably 2 μg / dose). Furthermore, the concentration of the aluminum phosphate adjuvant is 0.125 mg / dose to 0.5 mg / dose.

[0017] In one or more embodiments, the composition further comprises a surfactant, such as Tween 20 or Tween 80. Preferably, the concentration of the surfactant in the composition is 100-300 μg / dose, preferably 70-120 μg / dose.

[0018] The present invention also provides a multivalent immunogenic composition comprising a plurality of polysaccharide-protein conjugates and pharmaceutically acceptable excipients, wherein each polysaccharide-protein conjugate contains a capsular polysaccharide from a different serotype of Streptococcus pneumoniae conjugated to a carrier protein.

[0019] In one or more embodiments, the carrier protein comprises at least two carrier proteins.

[0020] In one or more embodiments, the carrier protein comprises (1) CRM197 and (2) TTD or a variant thereof.

[0021] In one or more embodiments, TTD is the C-terminal domain of TT.

[0022] In one or more embodiments, the TTD has the sequence set forth in SEQ ID NO:2, and the TTD variant has a sequence that has at least 90% sequence identity to SEQ ID NO:2.

[0023] In one or more embodiments, the serotypes include at least 2, 8, 9N, 10A, 11A, 12F, 15B, 17F, 20, 22F, and 33F. Preferably, the serotypes include the following 20 serotypes: 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, 33F, or the following 24 serotypes: 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F.

[0024] In one or more embodiments, in the polysaccharide protein conjugate, at least one or more or all capsular polysaccharides from serotypes 3, 5, 6B, 12F, 15B, 18C, 19F and 23F are conjugated to the carrier protein TTD or a variant thereof, respectively.

[0025] In one or more embodiments, the serotypes include the 20 serotypes, wherein capsular polysaccharides from 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 serotypes, including serotypes 3, 5, 6B, 12F, 15B, 18C, 19F and 23F, are conjugated to the carrier protein TTD or a variant thereof, respectively.

[0026] In one or more embodiments, the serotypes include the 20 serotypes, wherein the capsular polysaccharides from serotypes 3, 5, 6B, 12F, 15B, 18C, 19F and 23F are conjugated to the carrier protein TTD or its variants, respectively; and the capsular polysaccharides from serotypes 1, 4, 6A, 7F, 8, 9V, 10A, 11A, 14, 19A, 22F, 33F are conjugated to the carrier protein CRM197, respectively.

[0027] In one or more embodiments, the serotypes include the 24 serotypes, wherein capsular polysaccharides from 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24 serotypes, including serotypes 3, 5, 6B, 12F, 15B, 18C, 19F and 23F, are conjugated to the carrier protein TTD or a variant thereof, respectively.

[0028] In one or more embodiments, the serotypes include the 24 serotypes, wherein the capsular polysaccharides from serotypes 3, 5, 6A, 6B, 9N, 11A, 12F, 15B, 17F, 18C, 19A, 19F, 20, 23F, 33F are conjugated to the carrier protein TTD or its variants, respectively; and the capsular polysaccharides from serotypes 1, 2, 4, 7F, 8, 9V, 10A, 14, 22F are conjugated to the carrier protein CRM197, respectively.

[0029] In one or more embodiments, the serotypes include the 24 serotypes, wherein the capsular polysaccharides from serotypes 3, 5, 6B, 12F, 15B, 18C, 19F and 23F are conjugated to the carrier protein TTD or its variants, respectively; and the capsular polysaccharides from serotypes 1, 2, 4, 6A, 7F, 8, 9N, 9V, 10A, 11A, 14, 17F, 19A, 20, 22F, 33F are conjugated to the carrier protein CRM197, respectively.

[0030] In one or more embodiments, the weight ratio of capsular polysaccharide from serotype 3, 6B or 12F to any other capsular polysaccharide in the composition is 10:1 to 1:10, such as 5:1 to 1:5, preferably 2:1.

[0031] In one or more embodiments, the composition further comprises an adjuvant, such as an aluminum-based adjuvant.

[0032] In one or more embodiments, the adjuvant is selected from aluminum phosphate, aluminum sulfate, and aluminum hydroxide, preferably aluminum phosphate.

[0033] In one or more embodiments, the weight ratio of the conjugate to the adjuvant in the composition is 1:10 to 1:2, preferably 54:500 to 54:125.

[0034] In one or more embodiments, the composition is a preparation, the concentration of capsular polysaccharides from serotypes 3, 6B and 12F is each independently 1 to 8 ug / dose (preferably 4 μg / dose), the concentration of the remaining capsular polysaccharides is each independently 0.5 to 5 ug / dose (preferably 2 μg / dose), and the concentration of the aluminum phosphate adjuvant is 0.125 mg / dose to 0.5 mg / dose.

[0035] In one or more embodiments, the composition further comprises a surfactant, such as Tween 20 or Tween 80. Preferably, the concentration of the surfactant in the composition is 100-300 μg / dose, preferably 70-120 μg / dose.

[0036] In one or more embodiments, the pH of the composition is 5.0-7.0, preferably 5.0-6.2.

[0037] The present invention also provides use of the immunogenic composition described in the first aspect herein in the preparation of a medicament for inducing an immune response to a pneumococcal capsular polysaccharide conjugate and / or an immune response to tetanus toxin.

[0038] In one or more embodiments, the medicament is for preventing or treating pneumococcal infection and / or tetanus toxin infection.

[0039] The present invention also provides a method for inducing an immune response to a pneumococcal capsular polysaccharide conjugate and / or an immune response to tetanus toxin, comprising administering to a subject an immunologically effective amount of the immunogenic composition of the first aspect of the present invention.

[0040] The present invention also provides an immunogenic composition for passive immunity, comprising bactericidal antibodies targeting pneumococci, wherein the antibodies are obtained by immunizing a mammal with the immunogenic composition of any embodiment described herein. In one or more embodiments, the bactericidal antibodies are present in serum, a gamma globulin fraction, or a purified antibody preparation.

[0041] Advantages of the present invention:

[0042] The immunogenic composition of the present invention can effectively prevent invasive infections caused by 24 different serotypes of pneumococci, inducing relatively balanced and high immunogenicity against all serotypes. This immunogenicity is related to the ratio of the conjugate content for each serotype. The immunogenic composition of the present invention contains two different carrier proteins, both of which are non-toxic, thus eliminating the need for detoxification. This dual-carrier design reduces potential safety and immunosuppression risks. The immunogenic composition also provides protection against infection with tetanus toxin. BRIEF DESCRIPTION OF THE DRAWINGS

[0043] Figure 1. Comparison of immunogenicity of pneumococcal type 5 polysaccharide conjugates with different carriers.

[0044] Figure 2. Comparison of immunogenicity of 24-valent pneumococcal polysaccharide conjugate vaccine in mice at different adjuvant doses (same 13 serotypes as positive vaccine).

[0045] Figure 3. Comparison of immunogenicity of 24-valent pneumococcal polysaccharide conjugate vaccine in mice at different adjuvant doses (11 serotypes other than the 13 serotypes of the positive vaccine).

[0046] Figure 4. Comparison of immunogenicity of 24-valent pneumococcal polysaccharide conjugate vaccine at different pH in mice.

[0047] Figure 5. Comparison of immunogenicity of 13-valent serotypes of the same type in vivo in mice (D35).

[0048] Figure 6. Comparison of polysaccharide antibody titers (D35) against serotypes other than PCV13 vaccine in mice.

[0049] Figure 7. Comparison of 13-valent polysaccharide antibody titers of the same serotype in rabbits (D35).

[0050] Figure 8. Comparison of polysaccharide antibody titers (D35) against 13 other serotypes in rabbits.

[0051] Figure 9. Serum antibody titer levels after two doses of dual-vector and single-vector 24-valent pneumococcal polysaccharide conjugate vaccines.

[0052] Figure 10. Comparison of serum titers after two doses of PCV20 dual-vector and single-vector vaccines.

[0053] Figure 11. Comparison of serum titers after two doses of PCV24 dual-vector and single-vector vaccines.

[0054] Figure 12. Survival curve of the protection of mice challenged with type 3 pneumococcus by 24-valent pneumococcal polysaccharide conjugate vaccine.

[0055] Figure 13 shows the survival curve of the protective effect of 24-valent pneumococcal polysaccharide conjugate vaccine against 22F pneumococcus.

[0056] Figure 14. Comparison of TT antibody titers before and after the second dose of immunization. Group A received normal saline; Group B received diphtheria, pertussis, and tetanus vaccine; Group C received 24-valent pneumococcal polysaccharide conjugate vaccine.

[0057] Figure 15. Survival curve after tetanus toxin challenge. DETAILED DESCRIPTION

[0058] The present invention provides novel 20-valent or 24-valent pneumococcal capsular polysaccharide-protein conjugates, as well as corresponding immunogenic compositions and vaccine formulations. Compared to the marketed 13-valent polysaccharide conjugate vaccine, the vaccine formulation of the present invention induces higher antibody titers against some serotypes; exhibits good immunogenicity against serotypes other than the 13 serotypes; and induces superior in vivo immune protection compared to the 13-valent polysaccharide conjugate vaccine and the 23-valent polysaccharide vaccine. Furthermore, the inventors have discovered that using different carriers in different conjugates can induce higher antibody titers than a single-carrier vaccine.

[0059] The present invention first provides an immunogenic composition for inducing an immune response to a pneumococcal capsular polysaccharide conjugate in a mammal, thereby protecting the mammal from pneumococcal infection. The immunogenic composition comprises capsular polysaccharides from different serotypes of Streptococcus pneumoniae, the serotypes comprising at least 2, 8, 9N, 10A, 11A, 12F, 15B, 17F, 20, 22F, and 33F. Preferably, the serotypes comprise 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F.

[0060] The pneumococcal capsular polysaccharide present in the immunogenic composition may be in the form of a free polysaccharide or as a component of a conjugate in which the polysaccharide is covalently linked to a protein. In addition to the polysaccharide or polysaccharide-protein conjugate, the immunogenic composition may also contain a pharmaceutically acceptable carrier, such as saline, Ringer's solution, or phosphate-buffered saline.

[0061] In a preferred embodiment of the present invention, the capsular polysaccharide is covalently linked to a protein to form a conjugate. Thus, any protein or fragment thereof that is acceptable to an individual and that can induce an immune cell (e.g., T-cell) dependent response is suitable for conjugation to the pneumococcal capsular polysaccharide. Essentially any protein can be used as a conjugated protein. In particular, the selected protein must have at least one free amino group for conjugation to the polysaccharide. Preferably, the protein is any natural or recombinant bacterial protein and is itself an immunogen that induces a T-cell dependent response in young and adult mammals. Examples of such proteins include, but are not limited to, tetanus toxoid, cholera toxin, diphtheria toxoid and CRM197 or variants thereof. Other candidates for conjugated proteins include toxins or toxoids of Pseudomonas, Staphylococcus, Streptococcus, pertussis and enterotoxigenic bacteria including Escherichia coli.

[0062] In a preferred embodiment of the present invention, pneumococcal capsular polysaccharide is covalently linked to a protein to form a conjugate. Thus, any protein or fragment thereof that is acceptable to an individual and that can induce an immune cell (e.g., T-cell) dependent response is suitable for conjugation to pneumococcal capsular polysaccharide. Essentially any protein can be used as a conjugated protein. In particular, the selected protein must have at least one free amino group for conjugation to the polysaccharide. Preferably, the protein is any natural or recombinant bacterial protein and is itself an immunogen that induces a T-cell dependent response in young and adult mammals. Examples of such proteins include, but are not limited to, tetanus toxoid, cholera toxin, diphtheria toxoid. Other candidates for conjugated proteins include toxins or toxoids of Pseudomonas, Staphylococcus, Streptococcus, pertussis, and enterotoxigenic bacteria including Escherichia coli.

[0063] The protein (i.e., carrier protein) conjugated to the pneumococcal capsular polysaccharide can be any protein or fragment thereof that is acceptable to the individual and can induce an immune cell (e.g., T-cell) dependent response. Essentially, any protein can be used as a conjugated protein. In particular, the selected protein must have at least one free amino group for conjugation to the polysaccharide. Preferably, the protein is any natural or recombinant bacterial protein, and is itself an immunogen that induces a T-cell dependent response in young and adult mammals. Examples of such proteins include, but are not limited to, tetanus toxoid, cholera toxin, diphtheria toxoid. Other candidates for conjugated proteins include toxins or toxoids of Pseudomonas, Staphylococcus, Streptococcus, pertussis, and enterotoxigenic bacteria including Escherichia coli.

[0064] In addition, non-toxic variants of protein toxins, such as CRM197, can also be used. Preferably, such mutations retain the epitopes of the native toxin. These mutated toxins are referred to as "cross-reacting substances" or CRMs. The CRM197 carrier protein (NCBI: AMV91693.1, SEQ ID NO: 3) is a non-toxic variant of diphtheria toxin. This protein is non-toxic but retains the immunogenicity of diphtheria toxin (DT). Its fermentation and purification methods are available in published articles and patents (US5614382). The non-toxic variant protein of diphtheria toxin (CRM197) is a carrier protein that has been clinically proven to be safe and effective and has been widely used in marketed pneumococcal polysaccharide conjugate vaccines. Other diphtheria toxin variants are also suitable as carrier proteins. Pneumococcal polysaccharide fragments of these proteins can also be conjugated, provided that these fragments are long enough, i.e., preferably at least 10 amino acids, to determine the T-cell epitope.

[0065] Tetanus toxoid protein (TT) has been widely reported in the literature. The inventors have discovered a variant of the TT protein, the TTD protein. This protein is non-toxic but retains the immunogenicity of the TT protein. The TTD protein is located at the C-terminus of the heavy chain of the TT protein, has a relative molecular weight of 50 kDa, and is the receptor binding region of the toxin. It is non-toxic and has good immunogenicity. Its allergenicity is lower than that of tetanus toxoid, making it a potential antigen component and carrier protein for tetanus vaccines. TTD can be obtained by recombinant expression and purification (Immunobiology, Vol. 216, Issue 4, 2011, P 485-490). An exemplary method for expressing and purifying TTD includes cloning the DNA sequence expressing TTD (SEQ ID NO: 1) into the protein expression plasmid pET21, and constructing an engineered bacterium (e.g., Escherichia coli BL21 (DE3)) that recombinantly expresses the TTD protein (SEQ ID NO: 2). The recombinant engineered bacteria monoclonal colonies are picked and amplified in a suitable culture medium and conditions (for example, BL21 (DE3) is cultured in 10 mL of LB (Amp) liquid culture medium at 37°C and 250 rpm until OD600 reaches 0.8), an inducer is added for culture (for example, 0.1 mM IPTG is added and cultured at 25°C and 250 rpm for 4 hours), and then TTD is separated from the culture. The process of separating proteins from the culture is well known in the art, for example, the following steps: the culture solution is centrifuged at 8000 rpm and 4°C, and then the cells are broken (for example, ultrasonically broken) after resuspending with PBS, and the broken solution is centrifuged at 8000 rpm and 4°C to collect the supernatant containing the TTD protein. The method for purifying the TTD protein from the supernatant can use the method commonly used in the art for purifying proteins from liquids, for example, by ammonium sulfate precipitation, clarification filtration, combined chromatography such as ion exchange chromatography, composite media chromatography, and / or affinity chromatography, and the purity is above 95%. The molecular weight determined by mass spectrometry is consistent with the theoretical molecular weight.

[0066] Other suitable carrier proteins include inactivated bacterial toxins such as tetanus toxoid, pertussis toxoid, cholera toxoid (see, for example, WO 2004 / 083251), E. coli LT, E. coli ST, and exotoxins from Pseudomonas aeruginosa. Bacterial outer membrane proteins such as outer membrane complex c (OMPC), porins, transferrin binding protein, pneumolysin, pneumococcal surface protein A (PspA), pneumococcal adhesin protein (PsaA), C5a peptidase from group A or group B streptococci, or Haemophilus influenzae protein D can also be used. Other proteins such as ovalbumin, keyhole limpet hemocyanin (KLH), bovine serum albumin (BSA), or purified protein derivative of tuberculin (PPD) can also be used as carrier proteins.

[0067] Without materially affecting TTD activity (e.g., toxin-binding activity), those skilled in the art may modify one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 or more) amino acids in the TTD of the present invention to obtain TTD variants. These variants include (but are not limited to): deletion, insertion, and / or substitution of one or more (generally 1-50, preferably 1-30, more preferably 1-20, and most preferably 1-10) amino acids, as well as addition of one or more (generally within 20, preferably within 10, and more preferably within 5) amino acids to the C-terminus and / or N-terminus. In the art, conservative substitution with amino acids having similar or similar properties generally does not alter protein function. Amino acid residues suitable for conservative substitution are well known in the art. Such substituted amino acid residues may or may not be encoded by the genetic code. For example, addition of one or more amino acids to the C-terminus and / or N-terminus generally does not alter protein function. All of these are considered to be within the scope of protection of the present invention. TTD variants described herein include TTD variants that have at least 90% (eg, at least 95%, at least 98%, at least 99%) sequence identity to the TTD set forth in SEQ ID NO: 2 and retain its toxin binding activity.

[0068] The inventors have discovered that the immunogenic composition formed by conjugating multiple serotype polysaccharides using different carrier proteins and mixing them together has better immunogenicity and lower immunosuppression risk. Exemplarily, the immunogenic composition contains at least two carrier proteins, such as CRM197 and TTD or variants thereof. In a preferred embodiment, 20 or 24 pneumococcal polysaccharides of the present invention are chemically coupled with CRM197 and TTD carrier proteins to prepare polysaccharide-protein conjugates. The resulting polysaccharide-protein conjugates of different serotypes have good physicochemical properties, such as a polysaccharide-protein ratio between 0.5 and 3.0, a free sugar content below 20%, and other residual impurities are controlled within a very low range.

[0069] In some embodiments, in the polysaccharide-protein conjugate, at least one or more or all capsular polysaccharides from serotypes 3, 5, 6B, 12F, 15B, 18C, 19F, and 23F are conjugated to the carrier protein TTD or a variant thereof. Further, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or 24 serotypes including serotypes 3, 5, 6B, 12F, 15B, 18C, 19F, and 23F are conjugated to the carrier protein TTD or a variant thereof. Preferably, capsular polysaccharides from serotypes 3, 5, 6B, 12F, 15B, 18C, 19F and 23F are conjugated to the carrier protein TTD or its variants, respectively; capsular polysaccharides from serotypes 1, 2, 4, 6A, 7F, 8, 9N, 9V, 10A, 11A, 14, 17F, 19A, 20, 22F, 33F are conjugated to the carrier protein CRM197, respectively.

[0070] Herein, in the polysaccharide-protein conjugate or immunogenic composition, the ratio of capsular polysaccharides from different serotypes to carrier proteins is between 0.2-3.0, for example, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0 or a range between any two of the above values, preferably 0.5-2.5, 0.5-2.0, 0.5-1.5, more preferably 0.6-2.5, 0.6-2.0, 0.6-1.5.

[0071] In the polysaccharide-protein conjugate or immunogenic composition described herein, the weight ratio of the capsular polysaccharide from serotype 3, 6B or 12F to any other capsular polysaccharide is 10: 1 to 1: 10, such as 5: 1 to 1: 5, and preferably 2: 1. For example, the composition can be a preparation in which the concentration of the capsular polysaccharides from serotypes 3, 6B and 12F is each independently 1 to 8 μg / dose (preferably 4 μg / dose), the concentration of the remaining capsular polysaccharides is each independently 0.5 to 5 μg / dose (preferably 2 μg / dose), and the concentration of the aluminum phosphate adjuvant is 0.125 mg / dose to 0.5 mg / dose.

[0072] The immunogenic composition can be used as a vaccine and further contains an adjuvant such as an aluminum-based adjuvant (aluminum hydroxide, aluminum phosphate, or aluminum sulfate). In addition, the immunogenic composition described herein may also contain a surfactant, such as Tween 20 or Tween 80. The immunogenic composition of the present invention can induce active and passive protection against pneumococcal infection. For passive protection, immune antibodies are produced by immunizing a mammal with a vaccine made with the immunogenic composition of the present invention and then recovering the immune antibodies from the mammal. The present invention also provides a method for immunizing a subject against pneumococcal infection by administering an immunologically effective amount of the composition of the present invention.

[0073] Capsular polysaccharides are prepared by standard techniques known to those skilled in the art. In the present invention, capsular polysaccharides are prepared from serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 9N, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 20, 22F, 23F, and 33F of S. pneumoniae. These pneumococcal conjugates are prepared by separate methods and formulated into single-dose formulations.

[0074] Bacterial capsular polysaccharides are an important component of bacterial cells and are also important virulence factors for pathogenic bacteria. Pneumococcal capsular polysaccharides are released into the culture medium during bacterial culture. The pneumococcal capsular polysaccharides in the present invention are obtained by culturing, fermenting, and purifying pneumococcal bacteria of different serotypes. This technology is mature and has been used in the industry for many years, with multiple published articles or patent reports (US4242501). In one embodiment, each pneumococcal polysaccharide serotype is cultured in a soybean-based culture medium. The various polysaccharides are then purified by centrifugation, precipitation, ultrafiltration, and column chromatography (US4686102).

[0075] The specific method for preparing capsular polysaccharides is specifically reported in U.S. Patent No. 5,714,354. Pneumococcal bacterial culture, fermentation and polysaccharide preparation is a mature process (U.S. Pat. No. 4,686,102, U.S. Pat. No. 5,847,112). Simply put, different strains of Streptococcus pneumoniae are inoculated into a shake flask containing a culture medium (e.g., soybean culture medium), cultured overnight in a 37°C carbon dioxide incubator, and the culture fluid is inoculated into a 10-liter fermenter for fermentation for 6-12 hours. After the culture is completed, a DOC inactivator is added for sterilization and inactivation. The clarified culture fluid is harvested by centrifugation, and a CTAB precipitant is added to the clarified culture fluid to obtain a crude precipitated complex sugar, which is then purified through a series of precipitation, washing, and chromatography to obtain a refined polysaccharide.

[0076] The purification method of pneumococcal capsular polysaccharide is also a conventional technique in the art, for example, by an organic solvent-free method (U.S. Patent No. 5,714,354). The general purification process of the polysaccharide includes, but is not limited to, adding a NaCl solution to dissolve the complex sugar, dissolving it with a NaCl solution and centrifuging it to obtain the supernatant, adding alcohol to remove impurities and precipitate the sugar, washing the precipitate multiple times to remove impurities, or utilizing chromatography such as an ion exchange column or a composite filler to purify the polysaccharide according to different glycoforms. In a specific embodiment, the purification process mainly includes centrifuging the bacteria-inactivated solution to separate the bacteria, harvesting the centrifuged supernatant, and then filtering through a 0.22 μm filter membrane and concentrating it through ultrafiltration with a 100 KD membrane package to obtain a polysaccharide fermentation concentrate. CTAB solution is added to the polysaccharide fermentation concentrate, stirred at room temperature, and centrifuged at 8000 rpm to collect the polysaccharide complex precipitate (for 7F, 14, and 33F polysaccharides, the supernatant is collected). The polysaccharide complex is then dissociated with a 0.25-0.5 M NaCl solution and then purified by precipitation, column chromatography, ultrafiltration, etc. to obtain a purified polysaccharide solution. The polysaccharide solution is filtered through a 0.22 μm membrane and stored at low temperature.

[0077] Methods for quality analysis of the obtained polysaccharides are known in the art, for example, by nuclear magnetic resonance. Specifically, the prepared different types of pneumococcal capsular polysaccharides are identified by serotype using specific serum, the chemical structure of the pneumococcal polysaccharide is analyzed by nuclear magnetic resonance spectroscopy (NMR), and the content of functional groups (such as rhamnose, uronic acid, O-acetyl and other components) contained in the polysaccharide can be determined by chemical colorimetric methods. It is determined that the various physical and chemical indicators of the polysaccharide meet the standards for pneumococcal polysaccharides established by the European Pharmacopoeia, and the content of major impurities such as protein and nucleic acid is less than 1%.

[0078] Many conjugation methods can be used to produce the polysaccharide-protein conjugates of the present invention. In the polysaccharide-protein binding reaction process, polysaccharide activation and protein conjugation steps are generally included. Chemical activation of the polysaccharide and subsequent conjugation to the carrier protein are achieved by conventional methods. See, for example, U.S. Patent Nos. 4,673,574 and 4,902,506. By controlling parameters such as the molecular weight of the polysaccharide, the polysaccharide activation reaction, the polysaccharide-protein reaction ratio, the reaction temperature, the reaction time, and the pH value of the reaction solution, the final polysaccharide-protein conjugate is obtained. The resulting polysaccharide-protein conjugate is further purified to remove unreacted materials and impurities, and its polysaccharide-protein cross-linking degree and residual impurities are quantified by mass analysis to ensure batch consistency and comparability.

[0079] Purified polysaccharides are chemically activated to enable them to react with carrier proteins. Depending on the characteristics of the polysaccharide, different chemical activation methods can be selected. Commonly used polysaccharide activation methods include cyanogen bromide (US6375846B1), hydrolysis (US4761283), 1-cyano-4-dimethylamino arsenic tetrafluoroborate (CDAP) (EP0720485), and periodate oxidation (US4711779). The activated polysaccharide can be separated from other impurities by ultrafiltration. After activation, the polysaccharide is reactive with the carrier protein.

[0080] For example, a selective oxidation reaction using periodate (e.g., sodium periodate) or its equivalent is used to oxidize the hydroxyl groups of the previous sugar moiety to form aldehyde groups. This forms an activated pneumococcal capsular polysaccharide, which can now be covalently linked to the selected protein carrier. For example, at room temperature, about 10 mg of polysaccharide is suitably oxidized with about 1 ml of a 20 mM sodium periodate solution for about 10-15 minutes; alternatively, 0.05-2 equivalents of periodate are added to the polysaccharide for oxidation for 12-24 hours. The reaction time can be varied with other amounts of periodate to obtain equivalent oxidation. The reduction and ring opening of the sugar activate the ortho-hydroxyl groups of the reducing sugar into aldehyde groups. After the polysaccharide activation is completed, the small molecules in the reaction can be removed by ultrafiltration concentration.

[0081] The preparation of the conjugate is by chemically coupling the polysaccharide fragments obtained by treating the purified and extracted pneumococcal outer membrane polysaccharide to a carrier protein. The polysaccharide-protein conjugate can be obtained by direct chemical coupling or by linker implementation, such as coupling using the linker adipic acid dihydrazide. Various chemical methods for conjugating polysaccharides to proteins are known and described in the literature. Common methods include cyanogen bromide method, CDAP method or reductive amination method (US5952454, EP0720485, US4711779). For example, U.S. Patent No. 4,644,059, which is incorporated herein by reference, describes a conjugate prepared using adipic acid dihydrazide (ADH) as a homobifunctional linker. U.S. Patent No. 4,695,624, which is also incorporated herein by reference, describes a method for preparing polysaccharides and preparing conjugates using intergeneric spacers. A comprehensive review of various preparation methods and factors used in conjugate design is discussed in Dick, William E., and Michel Beurret, Contrib. M.B. Immunol. (1989), Vol. 10, pp. 48-114, which is also incorporated herein by reference. Polysaccharide-protein conjugates obtained by conjugation can induce relatively strong immunogenicity, inducing specific antibodies against both the polysaccharide and the protein.

[0082] A preferred method for conjugating the various pneumococcal capsular polysaccharide-protein conjugates of the present invention is reductive amination. The activated pneumococcal capsular polysaccharide is conjugated to the selected conjugated protein by coupling the amino groups of the carrier protein to the aldehyde groups of the pneumococcal capsular polysaccharide in the presence of cyanoborohydride ions or another reducing agent. The pneumococcal capsular polysaccharide-protein conjugate obtained from the reductive amination process is preferably soluble in aqueous solution. This makes the pneumococcal capsular polysaccharide-protein conjugates of the present invention preferred candidates for use as vaccines. The conjugation conditions can be adjusted according to the molecular weight of the polysaccharide and the specific protein. In the reductive amination method, the ratio of polysaccharide to carrier protein is controlled between 0.5 and 3.0. During the reaction, 1.0 to 2.0 equivalents of sodium cyanoborohydride solution of the polysaccharide is added, followed by 2.0 equivalents of sodium borohydride solution. The incubation temperature can be room temperature, and the incubation time can be, for example, at least 12 hours. After the reaction is completed, the impurities or unreacted substrates in the reaction are removed by ultrafiltration or chromatography, and finally the solution is sterile filtered through a 0.22 μm filter and the polysaccharide-protein conjugate solution is stored at 2-8°C.

[0083] After conjugation of the capsular polysaccharide to the carrier protein, the polysaccharide-protein conjugate is purified by a variety of techniques, including concentration / diafiltration procedures, precipitation / elution, and column chromatography.

[0084] After purification of the complex carbohydrates, they are mixed to prepare the immunogenic composition of the present invention, which can be used as a vaccine. The preparation of the immunogenic composition of the present invention can be accomplished using methods well known in the art. For example, 20 or 24 individual pneumococcal conjugates can be formulated with pharmaceutically acceptable excipients to prepare the composition. Examples of such carriers include, but are not limited to, water, buffered saline, polyols (e.g., glycerol, propylene glycol, liquid polyethylene glycol), and glucose solutions.

[0085] In some embodiments, the immunogenic composition may include one or more adjuvants. As defined herein, an "adjuvant" is a substance used to enhance the immunogenicity of the immunogenic composition of the present invention. Thus, adjuvants are typically administered to enhance the immune response and are well known to those skilled in the art. Suitable adjuvants for enhancing the effectiveness of the composition include, but are not limited to: (1) aluminum salts, such as aluminum hydroxide, aluminum phosphate, aluminum sulfate, and the like; (2) oil-in-water emulsion formulations, such as MF59, SAF, Ribi™ Adjuvant System (RAS), (Corixa, Hamilton, MT); (3) saponin adjuvants, such as QuilA or STIMULON™ QS-21; (4) bacterial lipopolysaccharides (such as aminoalkyl glucosamine phosphate compounds (AGP) or derivatives or analogs thereof), synthetic polynucleotides (such as oligonucleotides containing CpG motifs); (5) cytokines, such as interleukins (e.g., IL-1, IL-2, IL-4, IL-5, IL-6, IL-7, IL- 12, IL-15, IL-18, etc.), interferons (e.g., gamma interferon), granulocyte macrophage colony stimulating factor (GM-CSF), macrophage colony stimulating factor (M-CSF), tumor necrosis factor (TNF), costimulatory molecules B7-1 and B7-2, etc.; (6) mucosal adjuvants, including protein toxins, recombinant protein subunits and nucleic acids, etc., including detoxified mutants of bacterial ADP-ribosylating toxins, such as wild-type or mutant cholera toxin (CT), pertussis toxin (PT), or Escherichia coli heat-labile toxin (LT) (see, for example, WO93 / 13302 and WO92 / 19265); and (7) other substances that act as immunostimulants to enhance the effectiveness of the composition. The amount of adjuvant used can be determined by those skilled in the art according to conventional techniques. Exemplarily, the concentration of the adjuvant (e.g., aluminum phosphate) in the immunogenic composition herein is 0.125 mg / dose to 0.5 mg / dose.

[0086] The immunogenic compositions and vaccines of the present invention can be used to protect or treat mammals (e.g., humans) susceptible to pneumococcal infection, which can be achieved by administering the vaccine systemically or by mucosal routes. The immunogenic compositions described herein can also be used to prepare a medicament for protecting against various pneumococcal infections.

[0087] The immunogenic compositions of the present invention can be used as a means to increase antibodies for both prophylactic and diagnostic purposes. Diagnostics are particularly useful for monitoring and detecting various infections and diseases caused by pneumococci. Another embodiment of the present invention uses the immunogenic compositions as immunogens for active and passive immunogenic protection of individuals at risk for pneumococcal infection or disease. Immunizing antibodies for passive protection are generated by immunizing a mammal with any of the immunogenic compositions of the present invention and then recovering bactericidal antibodies from the mammal in the gamma-globulin fraction, either as serum or as specific antibodies. The vaccines of the present invention used herein can induce antibodies that are useful for providing protection against pneumococcal infection.

[0088] Alternatively, the pneumococcal capsular polysaccharide itself may be used as an immunizing agent, preferably in association with an adjuvant such as an aluminum-based adjuvant as an immunogenic composition. A further embodiment of the invention is the use of the immunogenic composition as an immunogenic protection against pneumococcal infection.

[0089] The immunogenic compositions and vaccines of the present invention can typically be formed by dispersing the pneumococcal capsular polysaccharide or conjugate into suitable pharmaceutically acceptable excipients. Such excipients include, but are not limited to, diluents, carriers, solubilizers, emulsifiers, preservatives, and / or adjuvants. Excipients are preferably non-toxic to the recipient at the dosage and concentration employed, for example, saline, buffer, glucose, water, glycerol, ethanol, and combinations thereof. In certain embodiments, the compositions may contain substances for improving, maintaining, or preserving, for example, the pH, osmotic properties, viscosity, clarity, color, isotonicity, odor, sterility, stability, dissolution or release rate, absorption, or penetration of the composition. Such substances are known in the art. The optimal pharmaceutical composition can be determined based on the intended route of administration, mode of delivery, and desired dosage. Additives commonly used in vaccines may also be present, for example, stabilizers such as lactose or sorbitol and adjuvants such as aluminum phosphate, aluminum hydroxide, aluminum sulfate, CpG, monophosphoryl lipid A, QS21, MF59, or stearoyl tyrosine.

[0090] The protective or therapeutic effects of the immunogenic compositions and vaccines of the present invention can be achieved by administering the vaccine systemically or by mucosal routes. Such administration includes parenteral administration, such as by injection via intramuscular, intraperitoneal, intradermal, or subcutaneous routes, or by mucosal administration to the oral / digestive, respiratory, or genitourinary tracts. In one embodiment, intranasal administration is used to treat pneumonia or otitis media.

[0091] The dosage of the immunogenic composition should be a dosage that can achieve an immunogenic effect. The amount of conjugate in each vaccine dose is selected as an amount that induces immune protection without significant adverse effects. Such an amount can vary depending on the pneumococcal serotype. Typically, each dose will contain 0.01 μg to 100 μg of polysaccharide or conjugate, for example 0.1 μg to 10 μg, or 1 μg to 5 μg. The dosage is usually in the range of about 0.01 μg to about 10 μg per kilogram of body weight. A range of optimal immunizing doses can be given. A unit dose of the vaccine may contain an amount of about 0.01 μg to about 100 μg of meningococcal capsular polysaccharide or conjugate, for example 0.1 μg to 10 μg, or 1 μg to 5 μg.

[0092] The optimal amounts of the components of a particular vaccine are determined by standard studies involving observation of an appropriate immune response in a subject. Following the initial vaccination, the subject may receive one or more booster immunizations at adequate intervals. The immunogenic compositions of the present invention are suitable for use in infants, children, adolescents, and adults. The immunization schedule can be determined by an experienced clinician.

[0093] In a specific embodiment of the present invention, the 20- or 24-valent vaccine is a sterile liquid formulation of pneumococcal capsular polysaccharides of serotypes 1, 2, 4, 6A, 7F, 8, 9N, 9V, 10A, 11A, 14, 17F, 19A, 20, 22F, and 33F, each conjugated to CRM197, and pneumococcal capsular polysaccharides of serotypes 3, 5, 6B, 12F, 15B, 18C, 19F, and 23F, each conjugated to TTD. Each dose is formulated to contain: 2 μg of each saccharide, except for 4 μg of polysaccharide 3, 6B, or 12F; approximately 20-80 μg of CRM197 carrier protein; approximately 10-40 μg of TTD carrier protein; and 0.125 mg to 0.5 mg of aluminum phosphate adjuvant. The liquid is filled into a single-dose syringe without a preservative. After shaking, the vaccine is a homogenous, white suspension suitable for intramuscular administration.

[0094] Exemplary specific embodiments of the present application:

[0095] 1. An immunogenic composition comprising capsular polysaccharides from different serotypes of Streptococcus pneumoniae and a carrier, wherein the serotypes include at least 2, 8, 9N, 10A, 11A, 12F, 15B, 17F, 20, 22F and 33F.

[0096] Preferably, the serotypes include 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 serotypes selected from the group consisting of 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F and 33F, and the serotypes include at least 2, 8, 9N, 10A, 11A, 12F, 15B, 17F, 20, 22F and 33F.

[0097] 2. The immunogenic composition of claim 1, wherein the serotypes include the following 20 serotypes: 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F, or the following 24 serotypes: 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F,

[0098] Preferably, the carrier is selected from one or more of saline, Ringer's solution and phosphate buffered saline.

[0099] 3. The immunogenic composition according to item 1 or 2, characterized in that the immunogenic composition further contains an adjuvant.

[0100] Preferably, the adjuvant comprises one or more selected from aluminum-based adjuvants, monophosphoryl lipid A, QS21, CpG, MF59, stearoyl tyrosine, Freund's adjuvant and other mucosal adjuvants.

[0101] 4. The immunogenic composition according to item 1 or 2, wherein the weight ratio of the capsular polysaccharide from serotype 3, 6B or 12F to any other capsular polysaccharide is 10:1 to 1:10, for example 5:1 to 1:5.

[0102] Preferably, the composition is a preparation, wherein the concentrations of the capsular polysaccharides from serotypes 3, 6B and 12F are each independently 1 to 8 ug / dose, and the concentrations of the remaining capsular polysaccharides are each independently 0.5 to 5 ug / dose.

[0103] 5. A multivalent immunogenic composition comprising a plurality of polysaccharide-protein conjugates and a pharmaceutically acceptable excipient, wherein each polysaccharide-protein conjugate comprises a capsular polysaccharide from a different serotype of Streptococcus pneumoniae conjugated to a carrier protein,

[0104] Preferably, the carrier protein comprises at least two carrier proteins,

[0105] Preferably, the serotypes include at least 2, 8, 9N, 10A, 11A, 12F, 15B, 17F, 20, 22F and 33F; more preferably, the serotypes include the following 20 serotypes: 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, 33F, or the following 24 serotypes: 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F and 33F.

[0106] 6. The multivalent immunogenic composition according to item 5, wherein the carrier protein comprises (1) CRM197 and (2) TTD or a variant thereof,

[0107] Preferably, TTD is the C-terminal domain of TT,

[0108] More preferably, the TTD has the sequence shown in SEQ ID NO. 2, and the TTD variant has a sequence having at least 90% sequence identity with SEQ ID NO: 2.

[0109] 7. The multivalent immunogenic composition according to item 5 or 6, characterized in that in the polysaccharide-protein conjugate, at least one or more or all capsular polysaccharides from serotypes 3, 5, 6B, 12F, 15B, 18C, 19F and 23F are conjugated to the carrier protein TTD or a variant thereof, respectively.

[0110] Preferably,

[0111] The serotypes include the 20 serotypes, wherein capsular polysaccharides from 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 serotypes, including serotypes 3, 5, 6B, 12F, 15B, 18C, 19F and 23F, are conjugated to the carrier protein TTD or a variant thereof, respectively, or

[0112] The serotypes include the 24 serotypes, wherein capsular polysaccharides from 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24 serotypes, including serotypes 3, 5, 6B, 12F, 15B, 18C, 19F and 23F, are conjugated to the carrier protein TTD or a variant thereof, respectively,

[0113] More preferably,

[0114] The serotypes include the 20 serotypes, wherein the capsular polysaccharides from serotypes 3, 5, 6B, 12F, 15B, 18C, 19F and 23F are conjugated to the carrier protein TTD or its variants; the capsular polysaccharides from serotypes 1, 4, 6A, 7F, 8, 9V, 10A, 11A, 14, 19A, 22F, 33F are conjugated to the carrier protein CRM197, or

[0115] The serotypes include the 24 serotypes, wherein the capsular polysaccharides from serotypes 3, 5, 6A, 6B, 9N, 11A, 12F, 15B, 17F, 18C, 19A, 19F, 20, 23F, 33F are conjugated to the carrier protein TTD or its variants; the capsular polysaccharides from serotypes 1, 2, 4, 7F, 8, 9V, 10A, 14, 22F are conjugated to the carrier protein CRM197, or

[0116] The serotypes include the 24 serotypes, wherein the capsular polysaccharides from serotypes 3, 5, 6B, 12F, 15B, 18C, 19F and 23F are conjugated to the carrier protein TTD or its variants, respectively; and the capsular polysaccharides from serotypes 1, 2, 4, 6A, 7F, 8, 9N, 9V, 10A, 11A, 14, 17F, 19A, 20, 22F, 33F are conjugated to the carrier protein CRM197, respectively.

[0117] 8. The multivalent immunogenic composition according to item 5 or 6, wherein the multivalent immunogenic composition further has one or more characteristics selected from the following:

[0118] In the composition, the weight ratio of the capsular polysaccharide from serotype 3, 6B or 12F to any other capsular polysaccharide is 10:1 to 1:10, such as 5:1 to 1:5.

[0119] The composition is a preparation, wherein the concentrations of capsular polysaccharides from serotypes 3, 6B and 12F are independently 1 to 8 μg / dose, and the concentrations of the remaining capsular polysaccharides are independently 0.5 to 5 μg / dose.

[0120] The composition further comprises an adjuvant; preferably, the adjuvant comprises one or more selected from aluminum-based adjuvants, monophosphoryl lipid A, QS21, CpG, MF59, stearoyl tyrosine, Freund's adjuvant and other mucosal adjuvants,

[0121] In the composition, the weight ratio of the conjugate to the adjuvant is 1:10 to 1:2,

[0122] The composition further comprises a surfactant; preferably, the concentration of the surfactant in the composition is 100 to 300 μg / dose,

[0123] The pH of the composition is 5.0-7.0.

[0124] 9. Use of the immunogenic composition according to any one of items 1 to 8 for the preparation of a medicament for inducing an immune response to a pneumococcal capsular polysaccharide conjugate and / or an immune response to tetanus toxin,

[0125] Preferably, the medicament is used for preventing or treating pneumococcal infection and / or tetanus toxin infection.

[0126] 10. An immunogenic composition for inducing passive immunity, comprising bactericidal antibodies targeting pneumococci, said antibodies being obtained by immunizing a mammal with the immunogenic composition of any one of items 1 to 8.

[0127] Preferably, the bactericidal antibodies are present in serum, a gamma globulin fraction or a purified antibody preparation.

[0128] The present invention will be described below by way of specific examples. It should be understood that these examples are merely illustrative and are not intended to limit the scope of the present invention. The methods and materials used in the examples are, unless otherwise stated, conventional materials and methods in the art.

[0129] Example

[0130] Experimental methods

[0131] 1. Preparation of Pneumococcal Capsular Polysaccharide

[0132] Pneumococcal bacterial culture, fermentation, and polysaccharide production is a mature process (US4686102, US5847112). A strain library of pneumococcal strains (American Type Biorepository Collection) with different serotypes is prepared by culturing. One tube of pneumococcal strain from the strain library is inoculated into a shake flask containing soy culture medium and incubated overnight in a 37°C, 5-10% CO2 incubator. After incubation, the culture is examined microscopically. If normal, the culture is inoculated into a 10L fermenter and fermented at pH 7.0 and 37°C. After incubation, a 10% DOC solution is added to inactivate the pneumococcal bacteria, ensuring complete inactivation.

[0133] The purification of pneumococcal capsular polysaccharides is accomplished by an organic solvent-free method (U.S. Patent No. 5,714,354). The preparation and purification process primarily involves centrifuging a bacterial inactivation solution to separate the thalline, harvesting the centrifuged supernatant, and then filtering through a 0.22 μm membrane and concentrating through a 100 kDa membrane package ultrafiltration to obtain a pneumococcal polysaccharide fermentation concentrate. CTAB solution is added to the pneumococcal polysaccharide fermentation concentrate, stirred at room temperature, and centrifuged at 8000 rpm to collect the polysaccharide complex precipitate (for 7F, 14, and 33F polysaccharides, the supernatant is collected). The polysaccharide complex is then dissociated with a 0.25-0.5 M NaCl solution and purified by precipitation, column chromatography, ultrafiltration, and other purification processes to obtain a purified polysaccharide solution. The polysaccharide solution is filtered through a 0.22 μm membrane and stored at low temperatures.

[0134] The prepared pneumococcal capsular polysaccharides of different types were identified using specific sera. Their chemical structures were analyzed using nuclear magnetic resonance spectroscopy (NMR), and the content of functional groups (such as rhamnose, uronic acid, and O-acetyl groups) in the polysaccharides was determined using a chemical colorimetric method. The physicochemical properties of the polysaccharides were confirmed to meet the European Pharmacopoeia standards for pneumococcal polysaccharides, with the contents of major impurities such as protein and nucleic acid remaining below 1%.

[0135] 2. Preparation of carrier protein TTD

[0136] The optimized DNA sequence expressing TTD (SEQ ID NO: 1) was cloned into the protein expression plasmid pET21 to construct Escherichia coli BL21 (DE3) expressing the TTD protein (SEQ ID NO: 2). The recombinant BL21 (DE3) single clone was picked and placed in 10 mL of LB (Amp) liquid medium and cultured at 37°C and 250 rpm until the OD 600 After the pH value reaches 0.8, 0.1 mM IPTG is added and the culture is continued at 25°C and 250 rpm for 4 hours. The culture solution is centrifuged at 8000 rpm and 4°C, the bacteria are collected, and then resuspended with PBS and broken. The broken liquid is centrifuged at 8000 rpm and 4°C, and the supernatant is collected. The TTD protein is purified by ammonium sulfate precipitation, clarification filtration, and combined chromatography, with a purity of more than 95%. The molecular weight determined by mass spectrometry is consistent with the theoretical molecular weight, and the homogeneity of the TTD protein is confirmed by molecular sieve. The amino acid sequence of TTD is shown below:

[0137] 3. Preparation of the non-toxic variant of diphtheria toxin CRM197 protein

[0138] The CRM197 carrier protein is a non-toxic variant of diphtheria toxin (SEQ ID NO: 3). This protein is non-toxic but retains the immunogenicity of diphtheria toxin. Its fermentation and purification methods have been reported in published articles and patents (US5614382). Typically, the culture medium is inoculated with Corynebacterium diphtheriae bacteria, stirred at 37°C for 20-30 hours, and then the bacteria are removed by centrifugation, retaining the supernatant. The fermentation supernatant is then filtered through ultrafiltration and the solution is exchanged. Ammonium sulfate is then added to precipitate the precipitate, and the precipitate is collected. The precipitate is then dissolved, the solution is exchanged, and the CRM197 protein is purified by column chromatography to a purity exceeding 95% for use in conjugation reactions.

[0139] 4. Preparation of polysaccharide-protein conjugates

[0140] The preparation of polysaccharide-protein conjugates by coupling bacterial polysaccharides with carrier proteins is an effective way to improve the immunogenicity of bacterial polysaccharides. Polysaccharide-protein conjugates are widely used in the preparation of bacterial vaccines, such as the polysaccharide PRP-TT conjugate vaccine for Haemophilus influenzae type B and the polysaccharide-carrier protein conjugate vaccine for Necklacena A, C, Y, and W meningococcal bacteria. The preparation of polysaccharide-protein conjugates mainly involves two steps: hydrolysis or activation of the polysaccharide and conjugation of the polysaccharide to the protein. Polysaccharide activation can be further divided into different methods such as the CNBr method (US 4619828), hydrolysis (US 4761283), and sodium periodate oxidation (US 5306492). The activated polysaccharide can then be directly chemically conjugated to the carrier protein (US 4356170) or conjugated to the carrier protein via a small molecule linker.

[0141] The preparation of pneumococcal polysaccharide-protein conjugates mainly includes the following steps: polysaccharide treatment, polysaccharide activation, and polysaccharide-protein coupling.

[0142] Pretreatment of Pneumococcal Polysaccharides: Some serotypes, such as serotypes 1, 3, 4, 6A, 6B, 8, 10A, 11A, 12F, 15B, 18C, and 22F, can be treated with acid or alkaline hydrolysis (US5847112A) before oxidation to reduce their molecular weight or increase their oxidative binding efficiency. Other polysaccharides, such as serotypes 2, 6B, 7F, 8, 10A, 11A, 12F, 14, 15B, 19A, 19F, and 33F, can be treated with high-pressure homogenization to reduce their molecular weight.

[0143] Activation of pneumococcal polysaccharide: Polysaccharide activation is performed by adding sodium periodate solution (US4711779). The amount of periodate added is usually 0.05-2 equivalents of polysaccharide, and the oxidation time is 12-24 hours. After the polysaccharide activation is completed, the small molecules in the reaction are removed by ultrafiltration and concentration.

[0144] Preparation of Pneumococcal Polysaccharide-Protein Conjugates: Chemical conjugation of polysaccharides to proteins was performed via reductive amination (US5952454, EP0720485, US4711779). Polysaccharides from serotypes 1, 2, 4, 6A, 7F, 8, 9N, 9V, 10A, 11A, 14, 17F, 19A, 20, 22F, and 33F were conjugated to CRM97 to prepare polysaccharide-protein conjugates; polysaccharides from serotypes 3, 5, 6B, 12F, 15B, 18C, 19F, and 23F were conjugated to TTD to prepare polysaccharide-protein conjugates. During the conjugation reaction, the polysaccharide to carrier protein ratio was controlled between 0.5 and 2.5. During the reaction, 1.0 to 2.0 equivalents of sodium cyanoborohydride solution was added, followed by 2.0 equivalents of sodium borohydride solution. After the reaction is complete, the solution is exchanged by ultrafiltration or chromatography to remove impurities or unreacted substrate. Finally, the solution is sterile filtered through a 0.22 μm filter and stored at 2-8°C. All polysaccharide-protein conjugates are analyzed by mass, and the free polysaccharide content is controlled within 20%, the free protein content is within 2%, the polysaccharide-protein ratio is between 0.5-2.0, and the endotoxin and other impurity levels are controlled within safe and acceptable ranges.

[0145] 5. Preparation of multivalent pneumococcal polysaccharide-protein conjugate vaccine

[0146] There are 24 major pathogenic serotypes of pneumococcus: 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F. Each polysaccharide-protein monovalent conjugate stock solution is prepared by diluting it with a pH 6.0 buffer solution, mixing it, and then adding an aluminum phosphate adjuvant and stirring. The polysaccharide content of each conjugate is 2 to 4 micrograms per milliliter, and the aluminum phosphate adjuvant content is 0.125 to 0.5 milligrams per milliliter.

[0147] 6. Evaluation of immunogenicity of polysaccharide-protein conjugates in animals

[0148] Mouse Immunization Protocol: Aluminum phosphate adjuvant was added to the polyvalent vaccine stock solution to prepare the immune antigen. Six- to eight-week-old Balb / c mice were intraperitoneally immunized with 8 mice per group, each immunization dosed with 0.5 ml. Immunizations were performed on days 0, 14, and 21. Marketed vaccines (Pfizer's Prevnar 13 and Watson Bio's Woanxin) served as positive controls, and aluminum phosphate adjuvant served as a negative control. Blood was drawn on day 35 to evaluate the immunogenicity of the polysaccharide.

[0149] Rabbit immunization experimental plan: The polyvalent vaccine concentrate was added to aluminum phosphate adjuvant to prepare the immune antigen. New Zealand white rabbits weighing 2.0-2.5 kg were selected for thigh muscle immunization, with 8 rabbits in each group and each immunization dose of 0.5 ml. At the same time, PCV13 (Prevnar 13) was used as the positive vaccine for two doses of immunization, and blood was drawn on day 35 to evaluate the immunogenicity of its polysaccharide.

[0150] 7. Evaluation of polysaccharide immunogenicity by ELISA

[0151] Pneumonia polysaccharide was diluted with coating buffer and coated on a 96-well enzyme-labeled plate at 100 μl / well. The plate was incubated at 37°C and then washed. After treating the mouse and rabbit antisera with adsorbents, the serum was first diluted at 1:100, then 2.5-fold gradient dilution, 8 dilution gradients, and then added to the enzyme-labeled plate at 50 μl per well and incubated overnight. After washing the plate, the secondary antibody was diluted 1:10,000 and added to the enzyme-labeled plate at 100 μl per well. After incubation for 2 hours, the plate was washed and 1 mg / ml PNPP-Na colorimetric substrate was added at 100 μl per well. After incubation for 2 hours, 3M NaOH was added at 50 μl / well to stop the reaction and the OD was read on the machine. 405 A ratio of the OD value of the assay well to the OD value of the negative well greater than or equal to 2.1 was considered positive. The dilution that gave the highest positive result was defined as the antibody titer of each serum. The geometric mean of the antibody titers for each group of immunized animals was calculated, and the statistical significance between different groups was analyzed using the T-test.

[0152] Example 1: Comparison of immunogenicity of serotype 5 polysaccharide-CRM197 conjugate and pneumonia polysaccharide-TTD conjugate in mice

[0153] After adding aluminum phosphate adjuvant, 5PS-CRM197 conjugate and 5PS-TTD conjugate were immunized into BALB / c mice (5 mice / group) at 2 μg / dose on days 0, 14, and 28, respectively. Blood was collected on days 21 and 35 to detect antibody titers.

[0154] The results showed (Figure 1) that the titer level of the conjugate D35 with CRM197 as the carrier was 866.43, and the titer level of the conjugate D35 with TTD as the carrier was 16260.67. The immunogenicity of the polysaccharide conjugate with TTD as the carrier was higher than that of the polysaccharide conjugate with CRM197 as the carrier, and the difference was significant by Mann Whitney test analysis (P=0.0079).

[0155] Example 2: Comparison of immunogenicity of 24-valent pneumococcal polysaccharide conjugate vaccine in mice at different adjuvant doses

[0156] The immunogenicity of a 24-valent pneumococcal polysaccharide conjugate vaccine with aluminum phosphate adjuvant at doses of 0.5 mg, 0.25 mg, and 0.125 mg was evaluated in BALB / c mice. Six- to eight-week-old female BALB / c mice were randomly divided into groups of eight and immunized with 0.5 ml of the vaccine on days 0, 14, and 28. Blood was collected on day 35 for antibody titer determination. The immunogenicity data are shown in Figures 2 and 3.

[0157] Results showed that the immunogenicity of the 24-valent pneumococcal polysaccharide conjugate vaccine against 13 serotypes (those included in the positive vaccine) at different adjuvant doses was comparable to that of the marketed 13-valent conjugate vaccine. Furthermore, the vaccine demonstrated higher antibody titers against some serotypes, such as 6B, 18C, and 23F, compared to the 13-valent conjugate vaccine. Furthermore, the vaccine demonstrated good immunogenicity against 11 serotypes other than the 13.

[0158] Example 3: Comparison of immunogenicity of 24-valent pneumococcal polysaccharide conjugate vaccine in mice under different pH conditions

[0159] The immunogenicity of a 24-valent pneumococcal polysaccharide conjugate vaccine at different pH values ​​was evaluated in BALB / c mice. The 24-valent pneumococcal polysaccharide conjugate vaccine was evaluated in 6- to 8-week-old female BALB / c mice. Mice were randomly divided into 8 groups. Two immunizations (one dose each) were performed on days 0 and 14. Serum was collected on days 0 and 21, and serum polysaccharide antibody titers were measured by ELISA.

[0160] The comparison of serum antibody titers one week after the second dose (D21) of the 24-valent pneumococcal polysaccharide conjugate vaccine with a pH range of 5.0 to 6.2 is shown in Figure 4. After immunization with the 24-valent pneumococcal polysaccharide conjugate vaccine with a pH range of 5.0 to 6.2, there was no significant difference in the antibody titer against each serotype between the groups (P>0.05), and both can induce good immunogenicity.

[0161] Example 4: Comparison of immunogenicity of 24-valent pneumococcal polysaccharide conjugate vaccine and positive vaccine in mice

[0162] There are currently two 13-valent pneumococcal conjugate vaccines on the market. One is Prevnar 13, produced by Pfizer of the United States, which uses CRM197 as a carrier protein. The other is Woanxin, produced by Watson Biopharma Co., Ltd., which uses tetanus toxoid (TT) as a carrier protein.

[0163] BALB / c mice were immunized with 24-valent pneumococcal conjugate vaccine, Prevnar 13, Woanxin, and an adjuvant control group on days 0, 14, and 28, respectively, and the immunogenicity was evaluated on day 35, as shown in Figures 5 and 6.

[0164] The results show that:

[0165] (1) Compared with the CRM197 carrier protein-based Prevnar 13, the immunogenicity of the 24-valent pneumococcal conjugate vaccine was significantly higher than that of the control group. In addition, the antibody titers of serotype 18C, 5, 6A, 7F, and 23F were also higher than those of the control group.

[0166] (2) Comparison of the 24-valent pneumococcal conjugate vaccine with the TT carrier protein-based Woanxin revealed significant differences in serum antibody titers at day 35, as determined by the non-parametric Kruskal-Wallis test. Types 4, 6A, and 23F showed higher immunogenicity than Woanxin. Furthermore, the antibody titers for 5, 7F, and 9V were also higher than those in the control group.

[0167] (3) The 24-valent pneumococcal conjugate vaccine also induced good immunogenicity for serotypes other than PCV13 (Figure 6). The antibody titers of the 24-valent pneumococcal conjugate vaccine (PCV24) and the adjuvant control group on day 35 were analyzed using the Mann-Whitney test. There were significant differences (P < 0.05) for serotypes 2, 8, 9N, 11A, 15B, 17F, 20, and 33F, indicating that the PCV24 vaccine has good immunogenicity for serotypes other than PCV13. There was no significant difference between the 10A vaccine group and the adjuvant control group (P = 0.3068), which may be due to the higher background antibody titer level of 10A in experimental mice.

[0168] Example 5: Comparison of immunogenicity of 24-valent pneumococcal polysaccharide conjugate vaccine and positive vaccine in rabbits

[0169] PCV24 pneumococcal polysaccharide conjugate vaccine was prepared and used to immunize rabbits (8 / group). PCV13 (Prevnar 13) was used as a positive control, and normal saline was used as a negative control. After the first immunization, immunizations were continued three weeks apart. Two weeks after the second immunization (D35), blood was collected to measure the antibody titers against various types of polysaccharides in the serum (Figures 7 and 8).

[0170] Compared to PCV13 (Prevnar 13) (Figure 7), the second dose of PCV24 demonstrated immunogenicity comparable to that of marketed vaccines across 13 serotypes using T-tests. Eleven serotypes beyond the 13 serotypes also demonstrated good immunogenicity (Figure 8).

[0171] Example 6: Comparison of immunogenicity of dual-vector and single-vector 24-valent pneumococcal polysaccharide conjugate vaccines

[0172] To compare the immunogenicity of a 24-valent pneumococcal polysaccharide conjugate vaccine using two carrier proteins versus one carrier protein, two different 24-valent pneumococcal polysaccharide conjugate vaccines were prepared. In Group A, eight serotypes (serotypes 3, 5, 6B, 12F, 15B, 18C, 19F, and 23F) were treated with TTD as the carrier protein, while the remaining 16 serotypes were treated with CRM197 as the carrier protein. In Group B, all 24 serotypes were treated with CRM197 as the carrier protein.

[0173] The above two groups of vaccines were used to immunize New Zealand white rabbits, with 8 rabbits in each group, for a total of two immunizations, with an interval of three weeks. Serum was collected before immunization and two weeks after the second immunization to detect the titer levels of antibodies to various types of polysaccharides. The titers of the two groups of vaccines two weeks after the second immunization were converted to logarithms and statistically analyzed using multiple t tests. The results are shown in Figure 9.

[0174] As shown in Figure 9, across all 24 serotypes, the dual-vector vaccine group induced higher antibody titers than the single-vector vaccine group. Furthermore, for seven serotypes (serotypes 4, 5, 9V, 12F, 19A, 19F, and 23F), the induced antibody titers showed significant differences (P < 0.05), indicating that dual-vector vaccines can avoid the immunosuppression caused by a single vector.

[0175] Example 7: Comparison of immunogenicity of dual-vector and single-vector 20-valent pneumococcal polysaccharide conjugate vaccines

[0176] Two different 20-valent (1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, 33F) pneumococcal polysaccharide conjugate vaccines were formulated. In Group A, 8 serotypes (3, 5, 6B, 12F, 15B, 18C, 19F, and 23F) were carrier proteins, while the remaining 12 serotypes were carrier proteins of CRM197. In Group B, all 20 serotypes were carrier proteins of CRM197.

[0177] New Zealand white rabbits (8 rabbits per group) were immunized with the two vaccines described above twice, three weeks apart. Serum was collected before immunization and two weeks after the second immunization to measure antibody titers for various polysaccharide types. Serum titers two weeks after the second immunization were converted to logarithms and statistically analyzed using multiple t tests. The results are shown in Figure 10.

[0178] The results showed that there were 8 serotypes in the dual-vector vaccine group using TTD vectors (3, 5, 6B, 12F, 15B, 18C, 19F, and 23F). The antibody titers of these 8 serotypes were higher than those in the single-vector vaccine group, and there were significant differences in types 5 and 23F, P < 0.05.

[0179] The titer levels of 16 of the 20 serotypes in the dual-vector vaccine group (except 6A, 7F, 22F, and 33F) were higher than those in the single-vector vaccine group.

[0180] Example 8: Comparison of immunogenicity of dual-vector and single-vector 24-valent pneumococcal polysaccharide conjugate vaccines

[0181] Two different 24-valent (1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F) pneumococcal polysaccharide conjugate vaccines were formulated. In Group A, 15 serotypes (serotypes 3, 5, 6A, 6B, 9N, 11A, 12F, 15B, 17F, 18C, 19A, 19F, 20, 23F, and 33F) were carrier proteins, while the other nine serotypes were carrier proteins of CRM197. In Group B, all 24 serotypes were carrier proteins of CRM197.

[0182] New Zealand white rabbits (8 rabbits per group) were immunized with the two vaccines described above twice, three weeks apart. Serum was collected before immunization and two weeks after the second immunization to measure antibody titers for various polysaccharide types. Serum titers two weeks after the second immunization were converted to logarithms and statistically analyzed using multiple t tests. The results are shown in Figure 11.

[0183] The results showed that there were 15 serotypes in the dual-vector vaccine group using TTD vectors (3, 5, 6A, 6B, 9N, 11A, 12F, 15B, 17F, 18C, 19A, 19F, 20, 23F, and 33F), among which the antibody titer levels of 12 serotypes were not lower than those in the single-vector vaccine group, and there was a significant difference in 23F, P < 0.05.

[0184] Among the 24 serotypes of the dual-vector vaccine, the titer levels of 16 serotypes (except 1, 2, 3, 4, 8, 10A, 14, and 19F) were no lower than those of the single-vector vaccine group.

[0185] Example 9: Protective Effect of 24-valent Pneumococcal Polysaccharide Conjugate Vaccine against Type 3 Pneumococcus in BALB / c Mice

[0186] PCV13 (Watson, Woanxin) polysaccharide conjugate vaccine was used as a positive control and normal saline was used as a negative control. Two weeks after three doses of intraperitoneal immunization, 2×10 5 The nasal drip infection of Streptococcus pneumoniae type 3 was carried out by quantifying CFU of Streptococcus pneumoniae type 3. The survival rate within two weeks after the challenge was observed, and the protective effect of the 24-valent pneumococcal polysaccharide conjugate vaccine against the challenge of type 3 Streptococcus pneumoniae was analyzed.

[0187] The results ( FIG12 ) showed that the antibodies induced by the 24-valent pneumococcal polysaccharide conjugate vaccine had a 100% immune protection effect, which was superior to the 13-valent pneumococcal polysaccharide conjugate vaccine on the market, which had a protection rate of 89.9%.

[0188] Example 9: Protective Effect of 24-valent Pneumococcal Polysaccharide Conjugate Vaccine against Type 22F Pneumococcus in BALB / c Mice

[0189] The test used 23-valent pneumococcal polysaccharide vaccine (PPV23) as the positive control and normal saline as the negative control. Three weeks after intraperitoneal immunization of BALB / c mice, 1×10 8 The mice were challenged with intraperitoneal infection of Streptococcus pneumoniae type 22F (CFU). The protective effect of the 24-valent pneumococcal conjugate vaccine against type 22F pneumococcus was analyzed by the survival of the mice after infection.

[0190] The results (Figure 13) showed that the 24-valent vaccine had a 100% survival rate, compared to a 30% survival rate for the control PPV23 polysaccharide vaccine and a 20% survival rate for saline. The log-rank (Mantel-Cox) test showed a significant difference between the 24-valent vaccine and the control, P < 0.05 (P = 0.0027).

[0191] In summary, the 24-valent pneumococcal polysaccharide conjugate vaccine has a significant protective effect against type 22F pneumococcus compared with the PPV23 polysaccharide vaccine.

[0192] Example 10: Test on the protection of 24-valent pneumococcal polysaccharide conjugate vaccine against tetanus toxin

[0193] The 24-valent pneumococcal polysaccharide conjugate vaccine contains the TTD carrier protein, and the effectiveness of the vaccine was evaluated by a tetanus toxin challenge protection test in mice.

[0194] BALB / c mice were immunized with 24-valent pneumococcal polysaccharide conjugate vaccine by intraperitoneal injection on days 0 and 14. DTP vaccine was used as a positive control and saline was used as a negative control. On day 28, blood was collected to measure the antibody titer against tetanus toxoid (TT) in the serum (Figure 14, Group A: saline; Group B: DTP vaccine; Group C: 24-valent pneumococcal polysaccharide conjugate vaccine). Tetanus toxin (20LD 50 ), and the survival of mice was observed within two weeks ( FIG15 ).

[0195] As shown in Figure 14, TT antibody titers were significantly higher in Groups B, C, and D after the second dose compared to pre-immunization (P < 0.05). The higher TT antibody titers in Group B than in Group C may be due to the fact that the DTP vaccine is composed of TT, while the 24-valent pneumococcal polysaccharide conjugate vaccine uses TTD.

[0196] As shown in Figure 15 , all patients in the saline group died on the first day after intraperitoneal infection with tetanus toxin. The protection rate of the 24-valent pneumococcal polysaccharide conjugate vaccine was 80%, while the protection rate of the diphtheria, pertussis, and tetanus vaccine in the control group was 100%. This indicates that the 24-valent pneumococcal polysaccharide conjugate vaccine has a protective effect against tetanus toxin infection, and its effect is significantly better than that of the negative control.

Claims

1. An immunogenic composition comprising capsular polysaccharides from different serotypes of Streptococcus pneumoniae and a carrier, said serotypes comprising at least 2, 8, 9N, 10A, 11A, 12F, 15B, 17F, 20, 22F and 33F, Preferably, the serotypes include 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 serotypes selected from the group consisting of 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F and 33F, and the serotypes include at least 2, 8, 9N, 10A, 11A, 12F, 15B, 17F, 20, 22F and 33F.

2. The immunogenic composition according to claim 1, wherein The serotypes include the following 20 serotypes: 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, 33F, or the following 24 serotypes: 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F and 33F, Preferably, the carrier is selected from one or more of saline, Ringer's solution and phosphate buffered saline.

3. The immunogenic composition according to claim 1 or 2, wherein The immunogenic composition further comprises an adjuvant, Preferably, the adjuvant comprises one or more selected from aluminum-based adjuvants, monophosphoryl lipid A, QS21, CpG, MF59, stearoyl tyrosine, Freund's adjuvant and other mucosal adjuvants.

4. The immunogenic composition according to claim 1 or 2, wherein The weight ratio of the capsular polysaccharide from serotype 3, 6B or 12F to any other capsular polysaccharide is from 10:1 to 1:10, such as from 5:1 to 1:5, Preferably, the composition is a preparation, wherein the concentrations of the capsular polysaccharides from serotypes 3, 6B and 12F are each independently 1 to 8 ug / dose, and the concentrations of the remaining capsular polysaccharides are each independently 0.5 to 5 ug / dose.

5. A multivalent immunogenic composition comprising a plurality of polysaccharide-protein conjugates and a pharmaceutically acceptable excipient, wherein each polysaccharide-protein conjugate comprises a capsular polysaccharide from a different serotype of Streptococcus pneumoniae conjugated to a carrier protein, Preferably, the carrier protein comprises at least two carrier proteins, Preferably, the serotypes include at least 2, 8, 9N, 10A, 11A, 12F, 15B, 17F, 20, 22F and 33F; more preferably, the serotypes include the following 20 serotypes: 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, 33F, or the following 24 serotypes: 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F and 33F.

6. The multivalent immunogenic composition according to claim 5, wherein The carrier protein comprises (1) CRM197 and (2) TTD or a variant thereof, Preferably, TTD is the C-terminal domain of TT, More preferably, the TTD has the sequence shown in SEQ ID NO. 2, and the TTD variant has a sequence having at least 90% sequence identity with SEQ ID NO:

2.

7. The multivalent immunogenic composition according to claim 5 or 6, wherein In the polysaccharide-protein conjugate, at least one or more or all capsular polysaccharides from serotypes 3, 5, 6B, 12F, 15B, 18C, 19F and 23F are conjugated to the carrier protein TTD or a variant thereof, respectively. Preferably, The serotypes include the 20 serotypes, wherein capsular polysaccharides from 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 serotypes, including serotypes 3, 5, 6B, 12F, 15B, 18C, 19F and 23F, are conjugated to the carrier protein TTD or a variant thereof, respectively, or The serotypes include the 24 serotypes, wherein capsular polysaccharides from 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24 serotypes, including serotypes 3, 5, 6B, 12F, 15B, 18C, 19F and 23F, are conjugated to a carrier protein TTD or a variant thereof, respectively, More preferably, The serotypes include the 20 serotypes, wherein the capsular polysaccharides from serotypes 3, 5, 6B, 12F, 15B, 18C, 19F and 23F are conjugated to the carrier protein TTD or its variants; the capsular polysaccharides from serotypes 1, 4, 6A, 7F, 8, 9V, 10A, 11A, 14, 19A, 22F, 33F are conjugated to the carrier protein CRM197, or The serotypes include the 24 serotypes, wherein the capsular polysaccharides from serotypes 3, 5, 6A, 6B, 9N, 11A, 12F, 15B, 17F, 18C, 19A, 19F, 20, 23F, 33F are conjugated to the carrier protein TTD or its variants; the capsular polysaccharides from serotypes 1, 2, 4, 7F, 8, 9V, 10A, 14, 22F are conjugated to the carrier protein CRM197, or The serotypes include the 24 serotypes, wherein the capsular polysaccharides from serotypes 3, 5, 6B, 12F, 15B, 18C, 19F and 23F are conjugated to the carrier protein TTD or its variants, respectively; and the capsular polysaccharides from serotypes 1, 2, 4, 6A, 7F, 8, 9N, 9V, 10A, 11A, 14, 17F, 19A, 20, 22F, 33F are conjugated to the carrier protein CRM197, respectively.

8. The multivalent immunogenic composition according to claim 5 or 6, wherein The multivalent immunogenic composition further has one or more characteristics selected from the group consisting of: In the composition, the weight ratio of the capsular polysaccharide from serotype 3, 6B or 12F to any other capsular polysaccharide is 10:1 to 1:10, such as 5:1 to 1:

5. The composition is a preparation, wherein the concentrations of capsular polysaccharides from serotypes 3, 6B and 12F are independently 1 to 8 μg / dose, and the concentrations of the remaining capsular polysaccharides are independently 0.5 to 5 μg / dose. The composition further comprises an adjuvant; preferably, the adjuvant comprises one or more selected from aluminum-based adjuvants, monophosphoryl lipid A, QS21, CpG, MF59, stearoyl tyrosine, Freund's adjuvant and other mucosal adjuvants, In the composition, the weight ratio of the conjugate to the adjuvant is 1:10 to 1:2, The composition further comprises a surfactant; preferably, the concentration of the surfactant in the composition is 100 to 300 μg / dose, The pH of the composition is 5.0-7.

0.

9. Use of the immunogenic composition according to any one of claims 1 to 8 in the preparation of a medicament for inducing an immune response to a pneumococcal capsular polysaccharide conjugate and / or an immune response to tetanus toxin, Preferably, the medicament is used for preventing or treating pneumococcal infection and / or tetanus toxin infection.

10. An immune composition that induces passive immunity, comprising bactericidal antibodies targeting pneumococcus, wherein the antibodies are obtained by immunizing a mammal with the immunogenic composition of any one of claims 1 to 8. Preferably, the bactericidal antibodies are present in serum, a gamma globulin fraction or a purified antibody preparation.

Citation Information

Cited By

  • Immunogenic composition containing multivalent pneumococcal polysaccharide-protein conjugate as well as preparation method and application of immunogenic composition

    CN120754237A

  • Pneumococcus polysaccharide-protein conjugate composition as well as preparation method and application thereof

    CN122537518A